Search Results for "antipsychotics"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for antipsychotics. Results 81 to 87 of 87 total matches.
Ropinirole for Restless Legs Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005 (Issue 1214)
, antipsychotics, antidepressants) may
cause additive sedative effects when taken with
ropinirole.
DOSAGE ...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
antipsychotics in patients
with comorbid depression or psychotic disorders,
respectively. The antidepressant ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Drugs for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023 (Issue 1672)
,
antipsychotics) can result in additive
adverse effects.
Darifenacin, solifenacin, tolterodine, fesoterodine ...
In overactive bladder, involuntary bladder contractions
due to detrusor overactivity result in urinary
urgency, frequency, nocturia, and incontinence.
The prevalence of the disorder increases with age.
Nonpharmacologic treatment, including bladder
training, urge suppression, pelvic floor muscle
exercises, constipation management, modification of
fluid intake, and avoidance of dietary irritants such as
alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5 doi:10.58347/tml.2023.1672a | Show Introduction Hide Introduction
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
antidepressants, antipsychotics, beta
blockers, and class 1C antiarrhythmics are CYP2D6
substrates and should ...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Drugs for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
,
a serotonin reuptake inhibitor, a monoamine oxidase
(MAO) inhibitor, other opioids, or an antipsychotic
drug ...
Many different drugs are used for treatment of
osteoarthritis pain, but none of them prevent
progression of the disease. Nonpharmacologic
approaches including weight management, exercise,
tai chi, physical therapy, assistive devices, and total
joint arthroplasty can also be used. The American
College of Rheumatology (ACR) has published new
guidelines for the management of osteoarthritis of the
hip, hand, and knee.
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020 (Issue 1590)
27, 2020
diagnosis of psychosis and a prescription for an
antipsychotic medication. During a median ...
Attention-deficit/hyperactivity disorder (ADHD) is a
chronic neurodevelopmental disorder that has been
diagnosed in up to 10% of school-age children in the
US and frequently persists into adulthood. A study in
a large Danish cohort found that ADHD was associated
with higher mortality rates in children, adolescents,
and adults, mainly due to accidents. Pharmacologic
treatment of ADHD in children has been reported to
decrease the risk of substance abuse in adolescents,
and use of ADHD medications in adults has been
associated with a reduced risk of serious traffic
accidents and...
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
, an SSRI, an MAO
inhibitor, other opioids, or an antipsychotic drug may
be at increased risk ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.